The global secondary progressive multiple sclerosis drug market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). Secondary progressive MS (SPMS) is a form of MS that occurs after relapsing-remitting MS. The disease varies across individuals and does not occur in all the patients who priorly have RRMS. The major factor contributing to the growth of the market is the increasing prevalence of the disease across the globe.
Get Free Sample link @ https://www.omrglobal.com/request-sample/secondary-progressive-multiple-sclerosis-drug-market
According to the National Multiple Sclerosis Society (NMSS), an estimated 50% of patients who are diagnosed with relapsing-remitting MS (RRMS) would transition to secondary-progressive MS (SPMS) within 10 years. Additionally, within 25 years, 90% of patients who are diagnosed with relapsing-remitting MS (RRMS) would evolve to secondary-progressive MS (SPMS). Hence, the rising prevalence of the disease is driving the demand for secondary progressive multiple sclerosis drugs.
Some major players operating in the market include Actelion Ltd., Biogen Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2019, Novartis announced the approval of Mayzent (siponimod) from the FDA. It is an oral drug used for the treatment of relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) in adults.
Full report of Secondary Progressive Multiple Sclerosis Drug Market available @ https://www.omrglobal.com/industry-reports/secondary-progressive-multiple-sclerosis-drug-market
Market Coverage
- Segment Covered-
o By Type
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Actelion Ltd., Biogen Inc., and Novartis International AG, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Secondary Progressive Multiple Sclerosis Drug Market Report by Segment
By Type
- Inebilizumab
- GLX-1112
- DC-TAB
- Etomoxir
- IB-MS
- Others
By Application
- Hospital
- Clinic
- Others
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/secondary-progressive-multiple-sclerosis-drug-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
